Navigation Links
Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations
Date:8/3/2009

ng cancer were diagnosed worldwide, with 1.31 million people dying from the disease.( )In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).

About Boehringer Ingelheim in Oncology

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need, including various solid tumors and hematological cancers.

The current focus of research includes compounds in three areas: angiogenesis inhibition, signal transduction inhibition and cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III clinical development in NSCLC earlier in 2008 and was granted Fast Track designation for a third/fourth line treatment indication in NSCLC by the US Food & Drug Administration. In addition, the LUME-Lung Phase III clinical trial program, which is investigating BIBF 1120 in combination with standard second-line chemotherapy treatments for patients with advanced NSCLC, is ongoing. In the area of cell-cycle kinase inhibition, Boehringer Ingelheim is developing inhibitors of polo-like kinase 1 (Plk1), a protein that is involved in the processes of cell division. These molecules are in the early stages of clinical development.

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidia
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. AmeriCares and Boehringer Ingelheim Open New, Expanded Free Clinic to Help Families Hit Hardest by Economic Hardship
2. Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts
3. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
4. Final Patient Completes Treatment In Boehringer Ingelheims RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
5. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
6. Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines
7. Emdeon Inc. Commences U.S. Initial Public Offering of Class A Common Stock
8. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
9. HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Cogdell Spencer Announces Commencement of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... National Nutrition Month is an ... habits and commit to nutritious decisions that will affect their ... a recent study from the U.S. Department of Agriculture (USDA), ... Making healthy snack choices needs to be an essential piece ... on the go. , Each day, millions of Americans turn ...
(Date:3/29/2015)... 30, 2015 Over 50 million women ... to undiagnosed autoimmune, thyroid, or hormone disorders. , Dr. ... personally treated hundreds of patients dealing with these conditions, ... the treatment options for their ailments. Her new book, ... women living with fatigue, brain fog, and sleepless nights. ...
(Date:3/29/2015)... Adults who are comparing the different ... the web can now use the QuotesPros.com website for ... now be explored while researching the automated database now ... differences between what a term policy provides and what ... some men and women. Insurers typically provide base pricing ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... clinical trials and research, manage data results and ... their clients reach regulation standards. Contract research organizations ... medical device manufacturing sectors. Industry operators provide clients ... to late-stage clinical research for Food and Drug ...
(Date:3/29/2015)... California (PRWEB) March 29, 2015 ... a new transition from Pixel Film Studios, entitled TranSports. ... transitions made exclusively for Final Cut Pro X,” said ... our users the tools needed to effortlessly transition using ... introduces TranSports, a new and uniquely styled transition pack ...
Breaking Medicine News(10 mins):Health News:Benefits of Healthy Snacking — HealthyYOU Vending Machines Offer 21 Healthy Snack Selections for People on the Go 2Health News:Benefits of Healthy Snacking — HealthyYOU Vending Machines Offer 21 Healthy Snack Selections for People on the Go 3Health News:How to Turn Mid-life into the Good Life 2Health News:Permanent Life Insurance Quotes Now Offered Through Web Search System at Insurer Website Online 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... ... at conference, ATLANTA, Feb. 26 Pamela Bishop, head ... featured presenter at the,2008 Run Walk Ride Fundraising Conference (RWRFC) ... at 4:00 p.m. EST,providing an overview of ING,s successful cause-marketing ...
... Alimera Sciences has entered into a,second exclusive ... management -- specifically the reduction of reactive,oxygen species ... The agreement gives Alimera the exclusive option ... as triphenylmethanes, as a potential,treatment for ocular disorders ...
... FRANCISCO, Feb. 26 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ... for the treatment of cardiovascular disease, announced today that,James ... VIA,will present a company update at the Susquehanna Second ... at 1:30 p.m. ET at the W,Hotel in New ...
... high blood sugar condition linked to high mortality ... effort is needed to deal with the effects of ... Heart Association scientific statement released Monday. , The statement ... also known as hyperglycemia, in people hospitalized with acute ...
... Quality Cardiology Center Seeks End to Soaring Health Costs, ... Hospital,one of the nation,s leading cardiology treatment centers, announced ... for one of the most common types of,open heart ... Wichita,Eagle published this week. "After carefully studying our costs ...
... Stock Exchange Symbol: CYT ... http://www.cryocath.com ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced that Chief ... 4, 2008. Effective April 7,2008, Ginette Gagne will take over the ...
Cached Medicine News:Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 2Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 3Health News:ING Run for Something Better to be Featured at 2008 Run Walk Ride Fundraising Conference 4Health News:Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants 2Health News:Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants 3Health News:National Effort Needed to Address Hyperglycemia in Heart Patients 2Health News:CryoCath Appoints New Chief Financial Officer 2
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
(Date:3/27/2015)... SALT LAKE CITY , March 27, 2015 ... Richard J. Linder has been appointed to the Company,s ... vacancy created by the death in November 2014 of board ... of Rich Linder to our Board of Directors ... Kelvyn Cullimore, Jr. , chairman and president of Dynatronics.  "Rich ...
(Date:3/27/2015)... TEMPLE, Texas , March 27, 2015 The ... relocate in April to a 5,000-square-foot building at 1802 South ... a geographic area designated by the City of ... Baylor Scott & White and the Central Texas Veterans Health ... office and laboratory space to early stage biotechnology and life ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... Calif., Oct. 3, 2011 VIVUS, Inc. (NASDAQ: ... presented at Obesity 2011:  The 29 th Annual ... Orlando, Florida. The presentations highlighted the long-term beneficial effects ... weight loss.  Specifically, Qnexa patients had significant improvement in ...
... KALONA, Iowa, Sept. 30, 2011 CIVCO Medical ... Andres Ramirez as Sales Director of Advanced Robotics ... international sales efforts for the Protura Robotic Patient ... System. (Logo:   http://photos.prnewswire.com/prnh/20110419/AQ85801LOGO ) ...
Cached Medicine Technology:Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 2Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 3Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 4Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 5Two-year Treatment With Qnexa Has Benefits Beyond Weight Loss 6CIVCO Appoints Andres Ramirez Sales Director of Advanced Robotics and Workflow Solutions 2
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Gills Colibri forceps, very fine pointed tips....
Castroviejo tying forceps, tying platforms, straight, 0.3 mm teeth....
Microsurgical straight forceps made of titanium has straight shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Medicine Products: